Compounds > mirogabalin
Page last updated: 2024-11-13

mirogabalin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

mirogabalin: for the treatment of diabetic peripheral neuropathic pain [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID59509752
CHEMBL ID3545125
SCHEMBL ID1816421
MeSH IDM000606774

Synonyms (44)

Synonym
S6632
ds 5565
((1r,5s,6s)-6-(aminomethyl)-3-ethylbicyclo(3.2.0)hept-3-en-6-yl)acetic acid
1138245-13-2
mirogabalin
mirogabalin [inn]
unii-s7lk2kdm5u
mirogabalin [usan:inn]
a 200-0700
s7lk2kdm5u ,
aminomethyl)-3-ethyl-bicyclo(3.2.0)hept-3-ene-6-acetic acid
bicyclo(3.2.0)hept-3-ene-6-acetic acid, 6-(aminomethyl)-3-ethyl-, (1r,5s,6s)-
a200-0700
[(1r,5s,6s)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid
mirogabalin [who-dd]
a-200-0700
mirogabalin [usan]
SCHEMBL1816421
gtpl8303
2-[(1r,5s,6s)-6-(aminomethyl)-3-ethyl-6-bicyclo[3.2.0]hept-3-enyl]acetic acid
AC-29882
CHEMBL3545125
2-((1r,5s,6s)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl)acetic acid
AS-73453
2-[(1r,5s,6s)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid
CS-6008
HY-12650
EX-A1736
bicyclo[3.2.0]hept-3-ene-6-acetic acid, 6-(aminomethyl)-3-ethyl-, (1r,5s,6s)-
DB11825
AKOS032945006
BCP29010
[(1r,5s,6s)-6-aminomethyl-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid
FTBQORVNHOIASH-CKYFFXLPSA-N
D11203
mirogabalin (usan/inn)
AMY11272
mirogabalin-besylate
mirogabalin (ds-5565)
BM166964
gtpl12597
[3h]mirogabalin
DTXSID001032301
EN300-20087478

Research Excerpts

Overview

Mirogabalin is a novel gabapentinoid drug with a hydrophobic bicyclo substituent on the γ-aminobutyric acid moiety that targets the voltage-gated calcium channel subunit α. The drug demonstrated safety and efficacy in a multicenter, randomized, double-blind, placebo-controlled 14-week study in Asian patients with PHN.

ExcerptReferenceRelevance
"Mirogabalin is a novel α"( Analgesic characteristics of a newly developed α
Komatsu, S; Nakamura, S; Nonaka, T; Yamada, T; Yamamoto, T, )		1.57
"Mirogabalin is a treatment option for patients with neuropathic pain; however, safety, tolerability, and pharmacokinetics (PK) data specifically for Chinese individuals are limited to a single-dose study. "( Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of Mirogabalin in Healthy Chinese Participants: A Randomized, Double-Blind, Placebo-Controlled Study.
Cao, G; Guo, B; Hong, Z; Ishizuka, H; Li, Y; Liu, X; Nakatsu, T; Toyama, K; Wang, Y; Wu, H; Wu, J; Wu, X; Yu, J; Yu, P; Zhang, J, 2023)		2.58
"Mirogabalin is a novel gabapentinoid drug with a hydrophobic bicyclo substituent on the γ-aminobutyric acid moiety that targets the voltage-gated calcium channel subunit α"( Recognition Mechanism of a Novel Gabapentinoid Drug, Mirogabalin, for Recombinant Human α
Fujiyoshi, Y; Hanzawa, H; Hiroaki, Y; Irie, K; Kamegawa, A; Kawasaki, S; Kitano, Y; Kozai, D; Nishikawa, K; Numoto, N; Oshima, A; Shimada, K, 2023)		2.6
"Mirogabalin is a novel ligand for the α"( Anxiolytic effects of the novel α
Kitano, Y; Kobayashi, H; Murasawa, H; Saeki, K, 2020)		1.28
"Mirogabalin is a novel drug for alleviating peripheral neuropathic pain, available since April 2019 in Japan. "( [Analgesic Effects of Mirogabalin for Cancer Pain].
Nakanishi, K; Ota, C; Yomiya, K, 2020)		2.32
"Mirogabalin is a novel, selective oral α2δ ligand that demonstrated safety and efficacy in a multicenter, randomized, double-blind, placebo-controlled 14-week study in Asian patients with PHN."( Long-term safety and efficacy of mirogabalin in Asian patients with postherpetic neuralgia: Results from an open-label extension of a multicenter randomized, double-blind, placebo-controlled trial.
Kakehi, Y; Kato, J; Matsui, N; Murayama, E; Ohwada, S, 2020)		1.56
"Mirogabalin is a novel, preferentially selective α"( A Randomized, Placebo-Controlled, Double-Blind Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Repeated Doses of Mirogabalin in Healthy Asian Volunteers.
Brown, K; Dishy, V; Ishizuka, H; Jansen, M; Johnson, L; Ohwada, S; Warrington, S, 2018)		2.12
"Mirogabalin is an α"( Open-Label Single-Dose Study to Assess the Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics of Mirogabalin.
Duchin, K; Lasseter, K; Marbury, T; Senaldi, G; Warren, V; Zahir, H, 2018)		2.13
"Mirogabalin, which is a novel ligand for the α₂δ subunit of voltage-gated calcium channels, is under development for the treatment of pain associated with diabetic peripheral neuropathy and postherpetic neuralgia. "( Analgesic effects of the novel α₂δ ligand mirogabalin in a rat model of spinal cord injury.
Domon, Y; Kitano, Y; Makino, M, 2018)		2.19
"Mirogabalin, which is a novel ligand for the α₂δ subunit of voltage-gated calcium channels, is being developed for treating neuropathic pain including diabetic peripheral neuropathy and postherpetic neuralgia. "( Effects of mirogabalin, a novel ligand for the α₂δ subunit of voltage-gated calcium channels, on N-type calcium channel currents of rat dorsal root ganglion culture neurons.
Arakawa, N; Buisson, B; Domon, Y; Kitano, Y; Kubota, K; Saito, M; Sava, B; Tamura, S; Wakimoto, S, 2019)		2.35
"Mirogabalin (DS-5565) is an α2δ-1 ligand being developed for pain associated with diabetic peripheral neuropathy, fibromyalgia, and postherpetic neuralgia. "( Exposure-response modeling of average daily pain score, and dizziness and somnolence, for mirogabalin (DS-5565) in patients with diabetic peripheral neuropathic pain.
Frame, B; Hutmacher, MM; Merante, D; Miller, R; Truitt, K, 2016)		2.1

Effects

Mirogabalin has a potent pain-modulating effect with a unique high affinity and prolonged dissociation rate for the a2delta-1 subunit of voltage-gated calcium (Ca2+) channels.

Mirogabalin besylate has been approved in several countries to treat peripheral neuropathic pain.

ExcerptReferenceRelevance
"Mirogabalin has a potent pain-modulating effect with a unique high affinity and prolonged dissociation rate for the a2delta-1 subunit of voltage-gated calcium (Ca2+) channels (VGCCs) on the dorsal root ganglion resulting in more sustained analgesia compared with traditional gabapentinoids."( Mirogabalin besylate in the treatment of neuropathic pain.
Alam, U; Burgess, J; Frank, B; Javed, S; Malik, RA, 2020)		2.72
"Mirogabalin has a unique binding profile and long duration of action."( Short-term outcomes of mirogabalin in patients with peripheral neuropathic pain: a retrospective study.
Misawa, H; Nishida, K; Ozaki, T; Takei, Y; Takigawa, T; Tetsunaga, T; Tsuji, H; Yamane, K, 2020)		1.59
"Mirogabalin has been attracting attention for treating peripheral neuropathic pain. "( Relationship between the dose titration and adherence of mirogabalin in patients with peripheral neuropathic pain depending on renal function: a nationwide electronic medical record database study.
Kato, K; Kimura, T; Kodama, S; Shiosakai, K, 2023)		2.6
"Mirogabalin besylate has been approved in several countries to treat peripheral neuropathic pain. "( Safety and Efficacy of Mirogabalin for Peripheral Neuropathic Pain: Pooled Analysis of Two Pivotal Phase III Studies.
Baba, M; Kakehi, Y; Kato, J; Kuroha, M; Murayama, E; Ohwada, S; Wasaki, Y, 2021)		2.37

Treatment

Mirogabalin is a treatment option for patients with neuropathic pain. Data specifically for Chinese individuals are limited to a single-dose study.

ExcerptReferenceRelevance
"Mirogabalin is a treatment option for patients with neuropathic pain; however, safety, tolerability, and pharmacokinetics (PK) data specifically for Chinese individuals are limited to a single-dose study. "( Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of Mirogabalin in Healthy Chinese Participants: A Randomized, Double-Blind, Placebo-Controlled Study.
Cao, G; Guo, B; Hong, Z; Ishizuka, H; Li, Y; Liu, X; Nakatsu, T; Toyama, K; Wang, Y; Wu, H; Wu, J; Wu, X; Yu, J; Yu, P; Zhang, J, 2023)		2.58
"Mirogabalin treatment was significantly associated with a significant reduction in the average daily pain score (ADPS) compared with placebo over 7 weeks."( Efficacy and safety of mirogabalin treatment in patients with diabetic peripheral neuropathic pain: A systematic review and meta-analysis of randomised controlled trials.
Abu-Zaid, A; Alabdulwahed, A; Aldughaither, SM; Alduraibi, FM; Aljaroudi, AM; Alshareef, AA; Alyoubi, RA; Masoud, AT, 2021)		1.65

Toxicity

mirogabalin was safe and well tolerated in healthy Chinese participants at single and multiple doses of up to 15 mg twice-daily. Compared with placebo, mirogbalin was significantly associated with more adverse events of dizziness, increased weight, peripheral oedema and somnolence.

ExcerptReferenceRelevance
" Safety assessments included adverse events (AEs), clinical laboratory tests, and electrocardiograms."( Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study.
Feins, K; Hsu, C; Merante, D; Rosenstock, J; Sharma, U; Vinik, A, 2014)		0.71
" Adverse events were monitored throughout the study."( Long-term safety and efficacy of mirogabalin in Asian patients with diabetic peripheral neuropathic pain.
Baba, M; Kuroha, M; Matsui, N; Ohwada, S; Wasaki, Y, 2020)		0.84
" The most common treatment-emergent adverse events were nasopharyngitis, diabetic retinopathy, peripheral edema, somnolence, diarrhea, increased weight and dizziness."( Long-term safety and efficacy of mirogabalin in Asian patients with diabetic peripheral neuropathic pain.
Baba, M; Kuroha, M; Matsui, N; Ohwada, S; Wasaki, Y, 2020)		0.84
" Adverse events were monitored throughout the study."( Long-term safety and efficacy of mirogabalin in Asian patients with postherpetic neuralgia: Results from an open-label extension of a multicenter randomized, double-blind, placebo-controlled trial.
Kakehi, Y; Kato, J; Matsui, N; Murayama, E; Ohwada, S, 2020)		0.84
" Most treatment-emergent adverse events (TEAEs) were mild or moderate."( Long-term safety and efficacy of mirogabalin in Asian patients with postherpetic neuralgia: Results from an open-label extension of a multicenter randomized, double-blind, placebo-controlled trial.
Kakehi, Y; Kato, J; Matsui, N; Murayama, E; Ohwada, S, 2020)		0.84
" Compared with placebo, mirogabalin was significantly associated with more adverse events of dizziness, increased weight, peripheral oedema and somnolence."( Efficacy and safety of mirogabalin treatment in patients with diabetic peripheral neuropathic pain: A systematic review and meta-analysis of randomised controlled trials.
Abu-Zaid, A; Alabdulwahed, A; Aldughaither, SM; Alduraibi, FM; Aljaroudi, AM; Alshareef, AA; Alyoubi, RA; Masoud, AT, 2021)		1.24
" Besides, mirogabalin was largely safe and associated with some adverse events that could be managed conservatively."( Efficacy and safety of mirogabalin treatment in patients with diabetic peripheral neuropathic pain: A systematic review and meta-analysis of randomised controlled trials.
Abu-Zaid, A; Alabdulwahed, A; Aldughaither, SM; Alduraibi, FM; Aljaroudi, AM; Alshareef, AA; Alyoubi, RA; Masoud, AT, 2021)		1.33
" Safety was assessed based on treatment-emergent adverse events identified from the adverse events collected throughout both studies."( Safety and Efficacy of Mirogabalin for Peripheral Neuropathic Pain: Pooled Analysis of Two Pivotal Phase III Studies.
Baba, M; Kakehi, Y; Kato, J; Kuroha, M; Murayama, E; Ohwada, S; Wasaki, Y, 2021)		0.93
" Treatment-emergent adverse events included somnolence (3."( Safety and Efficacy of Mirogabalin for Peripheral Neuropathic Pain: Pooled Analysis of Two Pivotal Phase III Studies.
Baba, M; Kakehi, Y; Kato, J; Kuroha, M; Murayama, E; Ohwada, S; Wasaki, Y, 2021)		0.93
" The primary endpoints were PK, safety, and tolerability variables, including treatment-emergent adverse events (TEAEs), laboratory tests, and vital signs."( Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of Mirogabalin in Healthy Chinese Participants: A Randomized, Double-Blind, Placebo-Controlled Study.
Cao, G; Guo, B; Hong, Z; Ishizuka, H; Li, Y; Liu, X; Nakatsu, T; Toyama, K; Wang, Y; Wu, H; Wu, J; Wu, X; Yu, J; Yu, P; Zhang, J, 2023)		1.14
"Consistent with previous phase I studies in other populations, mirogabalin was safe and well tolerated in healthy Chinese participants at single and multiple doses of up to 15 mg twice-daily."( Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of Mirogabalin in Healthy Chinese Participants: A Randomized, Double-Blind, Placebo-Controlled Study.
Cao, G; Guo, B; Hong, Z; Ishizuka, H; Li, Y; Liu, X; Nakatsu, T; Toyama, K; Wang, Y; Wu, H; Wu, J; Wu, X; Yu, J; Yu, P; Zhang, J, 2023)		1.38
" prevalent users of mirogabalin and pregabalin in September 2020 and reported data regarding baseline and adverse events to the Japan Pharmaceutical Association using web-based questionnaires."( Safety of mirogabalin and pregabalin in Japanese patients with neuropathic pain: a retrospective cohort study.
Hashiba, H; Kamei, M; Miyazaki, C; Nakajima, R; Ooba, N, )		0.86
" Although serious events were not reported, a marked difference in HRs of common adverse events, including somnolence (1."( Safety of mirogabalin and pregabalin in Japanese patients with neuropathic pain: a retrospective cohort study.
Hashiba, H; Kamei, M; Miyazaki, C; Nakajima, R; Ooba, N, )		0.53
"Chemotherapy-induced peripheral neuropathy (CIPN) is a painful, dose-limiting adverse effect of commonly used chemotherapeutic agents."( Efficacy and safety of mirogabalin for chemotherapy-induced peripheral neuropathy: a prospective single-arm trial (MiroCIP study).
Denda, T; Kodama, S; Kogawa, T; Kuwabara, S; Misawa, S; Naito, Y; Shiosakai, K; Suichi, T; Suzuki, T; Takada, M, 2023)		1.22
" The safety endpoint was incidence of adverse events."( Efficacy and safety of mirogabalin for chemotherapy-induced peripheral neuropathy: a prospective single-arm trial (MiroCIP study).
Denda, T; Kodama, S; Kogawa, T; Kuwabara, S; Misawa, S; Naito, Y; Shiosakai, K; Suichi, T; Suzuki, T; Takada, M, 2023)		1.22
" There was no notable worsening of CIPN severity in terms of Common Terminology Criteria for Adverse Events grade or Modified Total Neuropathy Score-reduced, although use of pain medications during chemotherapy might cause worsening of CIPN due to underestimation of subjective symptoms."( Efficacy and safety of mirogabalin for chemotherapy-induced peripheral neuropathy: a prospective single-arm trial (MiroCIP study).
Denda, T; Kodama, S; Kogawa, T; Kuwabara, S; Misawa, S; Naito, Y; Shiosakai, K; Suichi, T; Suzuki, T; Takada, M, 2023)		1.22
"Intervention with mirogabalin during chemotherapy may be effective and safe for cancer patients with moderate to severe CIPN."( Efficacy and safety of mirogabalin for chemotherapy-induced peripheral neuropathy: a prospective single-arm trial (MiroCIP study).
Denda, T; Kodama, S; Kogawa, T; Kuwabara, S; Misawa, S; Naito, Y; Shiosakai, K; Suichi, T; Suzuki, T; Takada, M, 2023)		1.55

Pharmacokinetics

Three phase 1 pharmacokinetic (PK)/pharmacodynamics (PD) studies were conducted in healthy men and women to further characterize the safety, tolerability, and PK/PD of mirogabalin administration with or without food. Four randomized, double-blind, placebo-controlled, 4-period drug-drug interaction studies were done in healthy subjects.

ExcerptReferenceRelevance
"A population pharmacokinetic model was developed to describe plasma concentrations of mirogabalin and lactam metabolite, obtained following a single oral dose of 5 mg mirogabalin to subjects with varying degrees of renal function."( Population pharmacokinetic modeling and simulation for assessing renal impairment effect on the pharmacokinetics of mirogabalin.
Merante, D; Miller, R; Truitt, K; Yin, OQ, 2016)		0.87
"Four randomized, double-blind, placebo-controlled, 4-period drug-drug interaction studies were conducted in healthy subjects to evaluate the pharmacokinetic and pharmacodynamic (PD) interactions between mirogabalin and commonly used central nervous system depressants."( Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Mirogabalin When Coadministered With Lorazepam, Zolpidem, Tramadol, or Ethanol: Results From Drug-Drug Interaction Studies in Healthy Subjects.
Currie, A; Dishy, V; Dow, J; He, L; Ishizuka, H; Jansen, M; Mendell, J; Merante, D; Zahir, H, 2018)		0.91
"Three phase 1 pharmacokinetic (PK)/pharmacodynamics (PD) studies were conducted in healthy men and women to further characterize the safety, tolerability, and PK/PD of mirogabalin administration with or without food and to guide the dose selection and regimen for phase 2 and 3 clinical development."( Tolerability, pharmacokinetics, and pharmacodynamics of mirogabalin in healthy subjects: Results from phase 1 studies.
Brown, K; Dishy, V; He, L; Hsu, C; Mendell, J; Ohwada, S; Warren, V; Zahir, H, 2018)		0.92
" We investigated the pharmacokinetic parameters and bioequivalence of the 2 formulations, including the maximum plasma concentration and the area under the plasma concentration-time curve up to the last quantifiable time."( Pharmacokinetics and Bioequivalence of Mirogabalin Orally Disintegrating Tablets and Conventional Tablets in Healthy Japanese Participants.
Eto, T; Ishizuka, H; Shinohara, S; Suzuki, K; Toyama, K; Yoshiba, S; Yoshihara, K, 2023)		1.18

Compound-Compound Interactions

Four randomized, double-blind, placebo-controlled, 4-period drug-drug interaction studies were conducted in healthy subjects to evaluate the pharmacokinetic and pharmacodynamic (PD) interactions between mirogabalin and commonly used depressants.

ExcerptReferenceRelevance
"Four randomized, double-blind, placebo-controlled, 4-period drug-drug interaction studies were conducted in healthy subjects to evaluate the pharmacokinetic and pharmacodynamic (PD) interactions between mirogabalin and commonly used central nervous system depressants."( Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Mirogabalin When Coadministered With Lorazepam, Zolpidem, Tramadol, or Ethanol: Results From Drug-Drug Interaction Studies in Healthy Subjects.
Currie, A; Dishy, V; Dow, J; He, L; Ishizuka, H; Jansen, M; Mendell, J; Merante, D; Zahir, H, 2018)		0.91
" Coadministration of mirogabalin and metformin is well tolerated in healthy subjects with no evidence of a drug-drug interaction."( Effect of coadministration of metformin with mirogabalin: Results from a phase 1, randomized, open-label, drug-drug interaction study
.
Currie, A; Dow, J; He, L; Zahir, H; Zaidi, F, 2018)		1.06

Bioavailability

ExcerptReferenceRelevance
" After single doses of mirogabalin (15 mg), the bioavailability was considered equivalent in the fed and fasted states, indicating that mirogabalin can be taken without food restrictions."( Tolerability, pharmacokinetics, and pharmacodynamics of mirogabalin in healthy subjects: Results from phase 1 studies.
Brown, K; Dishy, V; He, L; Hsu, C; Mendell, J; Ohwada, S; Warren, V; Zahir, H, 2018)		1.04

Dosage Studied

Study showed the safety and stable pain management of a long-term flexible dosing regimen of mirogabalin 10 or 15 mg twice daily for 52 weeks in patients with PHN. Of 172 patients who completed the study, 149 received the highest dosage (15 mg twicedaily)

ExcerptRelevanceReference
" Patients received mirogabalin, initiated at 5 mg twice daily and increased to a flexible maintenance dosage of 10 or 15 mg twice daily."( Long-term safety and efficacy of mirogabalin in Asian patients with diabetic peripheral neuropathic pain.
Baba, M; Kuroha, M; Matsui, N; Ohwada, S; Wasaki, Y, 2020)		1.17
" Of 172 patients who completed the study, 149 received the highest dosage of mirogabalin (15 mg twice daily)."( Long-term safety and efficacy of mirogabalin in Asian patients with diabetic peripheral neuropathic pain.
Baba, M; Kuroha, M; Matsui, N; Ohwada, S; Wasaki, Y, 2020)		1.07
"This extension study showed the safety and efficacy of a long-term flexible dosing regimen of mirogabalin 10 or 15 mg twice daily in patients with DPNP."( Long-term safety and efficacy of mirogabalin in Asian patients with diabetic peripheral neuropathic pain.
Baba, M; Kuroha, M; Matsui, N; Ohwada, S; Wasaki, Y, 2020)		1.06
"This study showed the safety and stable pain management of a long-term flexible dosing regimen of mirogabalin 10 or 15 mg twice daily for 52 weeks in patients with PHN."( Long-term safety and efficacy of mirogabalin in Asian patients with postherpetic neuralgia: Results from an open-label extension of a multicenter randomized, double-blind, placebo-controlled trial.
Kakehi, Y; Kato, J; Matsui, N; Murayama, E; Ohwada, S, 2020)		1.06
" Administration of mirogabalin on a long-term basis is a flexible dosage regimen for patients with PHN."( The Clinical Application and Progress of Mirogabalin on Neuropathic Pain as a Novel Selective Gabapentinoids.
Duan, Y; Li, D; Lu, J; Tang, H, 2023)		1.5
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (55)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's22 (40.00)24.3611
2020's33 (60.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 56.70

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index56.70 (24.57)
Research Supply Index4.38 (2.92)
Research Growth Index4.71 (4.65)
Search Engine Demand Index90.59 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (56.70)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials21 (36.21%)5.53%
Reviews9 (15.52%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other28 (48.28%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
gamma-aminobutyric acid
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.. gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.		742amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid		human metabolite;
neurotransmitter;
Saccharomyces cerevisiae metabolite;
signalling molecule
cimetidine
Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.. cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.		5.5231aliphatic sulfide;
guanidines;
imidazoles;
nitrile		adjuvant;
analgesic;
anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		2.3110nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
gabapentin
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.. gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.		10.6540gamma-amino acidanticonvulsant;
calcium channel blocker;
environmental contaminant;
xenobiotic
lorazepam
Lorazepam: A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.		8.5611benzodiazepine
metformin
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289). metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.		9.0721guanidinesenvironmental contaminant;
geroprotector;
hypoglycemic agent;
xenobiotic
probenecid
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.. probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.		8.5611benzoic acids;
sulfonamide		uricosuric drug
zolpidem
Zolpidem: An imidazopyridine derivative and short-acting GABA-A receptor agonist that is used for the treatment of INSOMNIA.. zolpidem : An imidazo[1,2-a]pyridine compound having a 4-tolyl group at the 2-position, an N,N-dimethylcarbamoylmethyl group at the 3-position and a methyl substituent at the 6-position.		8.5611imidazopyridinecentral nervous system depressant;
GABA agonist;
sedative
tramadol
Tramadol: A narcotic analgesic proposed for severe pain. It may be habituating.. tramadol : A racemate consisting of equal amounts of (R,R)- and (S,S)-tramadol. A centrally acting synthetic opioid analgesic, used (as the hydrochloride salt) to treat moderately severe pain. The (R,R)-enantiomer exhibits ten-fold higher analgesic potency than the (S,S)-enantiomer. Originally developed by Gruenenthal GmbH and launched in 1977, it was subsequently isolated from the root bark of the South African tree Nauclea latifolia.. (R,R)-tramadol : A 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol in which both stereocentres have R-configuration; the (R,R)-enantiomer of the racemic opioid analgesic tramadol, it exhibits ten-fold higher analgesic potency than the (S,S)-enantiomer.		8.56112-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanoladrenergic uptake inhibitor;
antitussive;
capsaicin receptor antagonist;
delta-opioid receptor agonist;
kappa-opioid receptor agonist;
metabolite;
mu-opioid receptor agonist;
muscarinic antagonist;
nicotinic antagonist;
NMDA receptor antagonist;
opioid analgesic;
serotonergic antagonist;
serotonin uptake inhibitor
irinotecan
[no description available]		2.3110carbamate ester;
delta-lactone;
N-acylpiperidine;
pyranoindolizinoquinoline;
ring assembly;
tertiary alcohol;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug
capsaicin
ALGRX-4975: an injectable capsaicin (TRPV1 receptor agonist) formulation for longlasting pain relief. capsaicinoid : A family of aromatic fatty amides produced as secondary metabolites by chilli peppers.		2.610capsaicinoidnon-narcotic analgesic;
TRPV1 agonist;
voltage-gated sodium channel blocker
oxycodone
Oxycodone: A semisynthetic derivative of CODEINE.. oxycodone : A semisynthetic opioid of formula C18H21NO4 that is derived from thebaine. It is a moderately potent opioid analgesic, generally used for relief of moderate to severe pain.		2.610organic heteropentacyclic compound;
semisynthetic derivative		antitussive;
mu-opioid receptor agonist;
opioid analgesic
pregabalin
Pregabalin: A gamma-aminobutyric acid (GABA) derivative that functions as a CALCIUM CHANNEL BLOCKER and is used as an ANTICONVULSANT as well as an ANTI-ANXIETY AGENT. It is also used as an ANALGESIC in the treatment of NEUROPATHIC PAIN and FIBROMYALGIA.. pregabalin : A gamma-amino acid that is gamma-aminobutyric acid (GABA) carrying an isobutyl substitutent at the beta-position (the S-enantiomer). Binds with high affinity to the alpha2-delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues.		11.32156gamma-amino acidanticonvulsant;
calcium channel blocker
levoleucovorin
Levoleucovorin: A folate analog consisting of the pharmacologically active isomer of LEUCOVORIN.. (6S)-5-formyltetrahydrofolic acid : The pharmacologically active (6S)-stereoisomer of 5-formyltetrahydrofolic acid.		2.31105-formyltetrahydrofolic acidantineoplastic agent;
metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Shingles
[description not available]		04.0221
Disc, Herniated
[description not available]		02.3110
Prurigo
A name applied to several itchy skin eruptions of unknown cause. The characteristic course is the formation of a dome-shaped papule with a small transient vesicle on top, followed by crusting over or lichenification. (From Dorland, 27th ed)		07.3110
Herpes Zoster
An acute infectious, usually self-limited, disease believed to represent activation of latent varicella-zoster virus (HERPESVIRUS 3, HUMAN) in those who have been rendered partially immune after a previous attack of CHICKENPOX. It involves the SENSORY GANGLIA and their areas of innervation and is characterized by severe neuralgic pain along the distribution of the affected nerve and crops of clustered vesicles over the area. (From Dorland, 27th ed)		09.0221
Intervertebral Disc Displacement
An INTERVERTEBRAL DISC in which the NUCLEUS PULPOSUS has protruded through surrounding ANNULUS FIBROSUS. This occurs most frequently in the lower lumbar region.		02.3110
Adverse Drug Event
[description not available]		04.8532
Cancer of Pancreas
[description not available]		03.6150
Peripheral Nerve Diseases
[description not available]		04.2121
Pancreatic Neoplasms
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).		03.6150
Peripheral Nervous System Diseases
Diseases of the peripheral nerves external to the brain and spinal cord, which includes diseases of the nerve roots, ganglia, plexi, autonomic nerves, sensory nerves, and motor nerves.		04.2121
Drug-Related Side Effects and Adverse Reactions
Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.		04.8532
Cranial Nerve V Injury
[description not available]		02.4110
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.9430
Allodynia
[description not available]		03.4550
Nerve Pain
[description not available]		013.523517
Neuralgia
Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.		115.523517
Injuries, Spinal Cord
[description not available]		06.0854
Spinal Cord Injuries
Penetrating and non-penetrating injuries to the spinal cord resulting from traumatic external forces (e.g., WOUNDS, GUNSHOT; WHIPLASH INJURIES; etc.).		06.0854
Cancer-Associated Pain
[description not available]		07.7620
Carcinoma, Ductal, Pancreatic
[description not available]		02.610
Cancer Pain
Pain that may be caused by or related to cellular, tissue, and systemic changes that occur during NEOPLASM growth, tissue invasion, and METASTASIS.		07.7620
Carcinoma, Pancreatic Ductal
Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.		02.610
Encephalopathy, Toxic
[description not available]		02.610
Benign Neoplasms
[description not available]		02.610
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.610
Pain, Chronic
[description not available]		02.8220
Dry Eye
[description not available]		02.610
Dry Eye Syndromes
Corneal and conjunctival dryness due to deficient tear production, predominantly in menopausal and post-menopausal women. Filamentary keratitis or erosion of the conjunctival and corneal epithelium may be caused by these disorders. Sensation of the presence of a foreign body in the eye and burning of the eyes may occur.		02.610
Eye Pain
A dull or sharp painful sensation associated with the outer or inner structures of the eyeball, having different causes.		02.610
Chronic Pain
Aching sensation that persists for more than a few months. It may or may not be associated with trauma or disease, and may persist after the initial injury has healed. Its localization, character, and timing are more vague than with acute pain.		02.8220
Carcinoma, Non-Small Cell Lung
[description not available]		03.9911
Cancer of Lung
[description not available]		03.9911
Ache
[description not available]		06.7232
Carcinoma, Non-Small-Cell Lung
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.		03.9911
Lung Neoplasms
Tumors or cancer of the LUNG.		03.9911
Pain
An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.		18.7232
Anxiety
Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.		02.9430
Asymmetric Diabetic Proximal Motor Neuropathy
[description not available]		010.51110
Diabetic Neuropathies
Peripheral, autonomic, and cranial nerve disorders that are associated with DIABETES MELLITUS. These conditions usually result from diabetic microvascular injury involving small blood vessels that supply nerves (VASA NERVORUM). Relatively common conditions which may be associated with diabetic neuropathy include third nerve palsy (see OCULOMOTOR NERVE DISEASES); MONONEUROPATHY; mononeuropathy multiplex; diabetic amyotrophy; a painful POLYNEUROPATHY; autonomic neuropathy; and thoracoabdominal neuropathy. (From Adams et al., Principles of Neurology, 6th ed, p1325)		112.51110
Postherpetic Neuralgia
[description not available]		06.9242
Neuralgia, Postherpetic
Pain in nerves, frequently involving facial SKIN, resulting from the activation the latent varicella-zoster virus (HERPESVIRUS 3, HUMAN). The two forms of the condition preceding the pain are HERPES ZOSTER OTICUS; and HERPES ZOSTER OPHTHALMICUS. Following the healing of the rashes and blisters, the pain sometimes persists.		18.9242
Age-Related Memory Disorders
[description not available]		02.2510
Memory Disorders
Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions.		02.2510
Diffuse Myofascial Pain Syndrome
[description not available]		012.541916
Fibromyalgia
A common nonarticular rheumatic syndrome characterized by myalgia and multiple points of focal muscle tenderness to palpation (trigger points). Muscle pain is typically aggravated by inactivity or exposure to cold. This condition is often associated with general symptoms, such as sleep disturbances, fatigue, stiffness, HEADACHES, and occasionally DEPRESSION. There is significant overlap between fibromyalgia and the chronic fatigue syndrome (FATIGUE SYNDROME, CHRONIC). Fibromyalgia may arise as a primary or secondary disease process. It is most frequent in females aged 20 to 50 years. (From Adams et al., Principles of Neurology, 6th ed, p1494-95)		114.541916
Diabetes Mellitus
A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.		06.2241
Chronic Illness
[description not available]		02.3110
Cranial Nerve V Diseases
[description not available]		02.3110
Chronic Disease
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).		02.3110
Cognition Disorders
Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.		02.3110
Kidney Failure
A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.		02.1710
Renal Insufficiency
Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.		02.1710
Alloxan Diabetes
[description not available]		02.1710
Sleepiness
Compelling urge to sleep.		03.5611
Dizzyness
[description not available]		04.522
Dizziness
An imprecise term which may refer to a sense of spatial disorientation, motion of the environment, or lightheadedness.		09.522
Liver Dysfunction
[description not available]		03.5611
Liver Diseases
Pathological processes of the LIVER.		03.5611
Autoimmune Diabetes
[description not available]		04.4922
Diabetes Mellitus, Adult-Onset
[description not available]		04.4922
Diabetes Mellitus, Type 1
A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.		04.4922
Diabetes Mellitus, Type 2
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.		04.4922
Complications of Diabetes Mellitus
[description not available]		03.1210
Daytime Sleepiness
[description not available]		03.5111
Disorders of Excessive Somnolence
Disorders characterized by hypersomnolence during normal waking hours that may impair cognitive functioning. Subtypes include primary hypersomnia disorders (e.g., IDIOPATHIC HYPERSOMNOLENCE; NARCOLEPSY; and KLEINE-LEVIN SYNDROME) and secondary hypersomnia disorders where excessive somnolence can be attributed to a known cause (e.g., drug affect, MENTAL DISORDERS, and SLEEP APNEA SYNDROME). (From J Neurol Sci 1998 Jan 8;153(2):192-202; Thorpy, Principles and Practice of Sleep Medicine, 2nd ed, p320)		03.5111
Kidney Diseases
Pathological processes of the KIDNEY or its component tissues.		03.5111
Nervous System Disorders
[description not available]		03.9610
Nervous System Diseases
Diseases of the central and peripheral nervous system. This includes disorders of the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscle.		03.9610